Pharma Lord (Pvt) Ltd
Private pharmaceutical manufacturer · Lahore · Pakistan
Pakistan pharmaceutical manufacturer established in 2010 with oral solid, dry-powder and specialty product capabilities.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Pharma Lord (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Aadam House, 122-B, Venus Housing Society, Ferozepur Road, Lahore, Pakistan
- Website
- pharma-lord.com ↗
- Phone
- +92 300 5828186; +92 42 35807786
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Admox | Moxifloxacin | 400 mg | Tablet | 1x5 | 097382 | PKR 801.91 | PKR 160.38/tablet | 13% below median |
| Alord | Loratadine | 10 mg | Tablet | 10's | 119684 | PKR 83.38 | PKR 8.34/tablet | 42% below median |
| Cilpor Tabet | Ciprofloxacin | 250 mg | Tablet | 1x10 | 076834 | PKR 268.49 | PKR 26.85/tablet | 6% above median |
| Ciplor | Ciprofloxacin | 500 mg | Tablet | 1x10 | 076835 | PKR 371.74 | PKR 37.17/tablet | 13% below median |
| Ciplor | Ciprofloxacin | 250 mg/5 mL | Dry suspension | 60ml | 076845 | PKR 330.45 | PKR 5.51/mL | 9% above median |
| Ciplor | Ciprofloxacin | 125 mg/5 mL | Dry suspension | 60ml | 111772 | PKR 127.14 | PKR 2.12/mL | 40% below median |
| ClarySource observed | Clarithromycin | 250 mg/5 mL | Held for normalizationSource reported: Tablet · structural field conflict | 60ml | 088808Official source ↗ | No indexed price | — | — |
| ClarySource observed | Clarithromycin | 125 mg/5 mL | Held for normalizationSource reported: Tablet · structural field conflict | 60ml | 088809Official source ↗ | No indexed price | — | — |
| Clary | Clarithromycin | 250 mg | Tablet | 1x10 | 097389 | PKR 413.66 | PKR 41.37/tablet | 13% below median |
| Clary | Clarithromycin | 500 mg | Tablet | 1x10 | 097390 | PKR 675.29 | PKR 67.53/tablet | 20% below median |
| EBM | Ferrous sulfate + Folic acid | 200 mg + 0.1 mg | Capsule | 3x10 | 087921 | PKR 77.98 | PKR 2.60/capsule | 9% below median |
| Flufung | Fluconazole | 150 mg | Capsule | 1x1 | 088805 | PKR 267.92 | PKR 267.92/capsule | Near median |
| Flufung Dry | Fluconazole | 50 mg/5 mL | Dry suspension | 35ml | 088807 | PKR 407.70 | PKR 11.65/mL | Near median |
| Flutin | Fluoxetine | 20 mg | Capsule | 3x10 | 093751 | PKR 363.45 | PKR 12.12/capsule | 7% below median |
| Flutin | Fluoxetine | 20 mg | Capsule | 1x10 | 093751 | PKR 126.20 | PKR 12.62/capsule | Near median |
| Hydrolor | Hydroxychloroquine | 200 mg | Tablet | 5x10 | 105993 | PKR 675.31 | PKR 13.51/tablet | 7% below median |
| Hydrolor | Hydroxychloroquine | 200 mg | Tablet | 3x10 | 105993 | PKR 405.18 | PKR 13.51/tablet | 7% below median |
| Infix | Cefixime | 200 mg/5 mL | Suspension | 30ml | 086392 | PKR 404.31 | PKR 13.48/mL | Near median |
| Infix | Cefixime | 100 mg/5 mL | Suspension | 30ml | 086393 | PKR 330.39 | PKR 11.01/mL | Near median |
| Infix | Cefixime | 400 mg | Capsule | 1x5 | 086394 | PKR 604.43 | PKR 120.89/capsule | 7% above median |
| Irod | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 3x10 | 076837 | PKR 368.52 | PKR 12.28/tablet | 7% below median |
| Irod | Elemental iron + Folic acid | 100 mg + 0.35 mg | Tablet | 1x10 | 076837 | PKR 127.96 | PKR 12.80/tablet | No comparator |
| Irolex | Iron polymaltose complex | 150 mg | Capsule | 3x10 | 088803 | PKR 654.10 | PKR 21.80/capsule | 6% below median |
| Lestam | Levetiracetam | 250 mg | Tablet | 30's | 117526 | PKR 911.44 | PKR 30.38/tablet | 45% below median |
| Lestam | Levetiracetam | 250 mg | Tablet | 10's | 117526 | PKR 303.43 | PKR 30.34/tablet | 45% below median |
| Lestam | Levetiracetam | 500 mg | Tablet | 30's | 117527 | PKR 1,511.34 | PKR 50.38/tablet | 48% below median |
| Lestam | Levetiracetam | 500 mg | Tablet | 10's | 117527 | PKR 503.78 | PKR 50.38/tablet | 48% below median |
| Lordslin | Linezolid | 600 mg | Tablet | 2x6 | 097388 | PKR 4,315.12 | PKR 359.59/tablet | 9% below median |
| Lordslin | Linezolid | 100 mg/5 mL | Suspension | 60ml | 099880 | PKR 562.00 | PKR 9.37/mL | 15% below median |
| Lorgyl | Metronidazole | 400 mg | Tablet | 10x10 | 076839 | PKR 388.12 | PKR 3.88/tablet | 31% above median |
| Lorvit-C | Ascorbic acid | 500 mg | Chewable tablet | 1x40 | 105994 | PKR 53.06 | PKR 1.33/tablet | Near median |
| Macazit | Azithromycin | 250 mg | Capsule | 1x6 | 088804 | PKR 297.05 | PKR 49.51/capsule | Near median |
| Macazit | Azithromycin | 250 mg | Capsule | 1x10 | 088804 | PKR 495.07 | PKR 49.51/capsule | Near median |
| Macazit | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 088806 | PKR 320.35 | PKR 21.36/mL | Near median |
| Macazit | Azithromycin | 250 mg | Tablet | 1x6 | 105995 | PKR 225.10 | PKR 37.52/tablet | 20% below median |
| Macazit | Azithromycin | 500 mg | Tablet | 1x6 | 107062 | PKR 388.49 | PKR 64.75/tablet | 24% below median |
| Omelor | Omeprazole | 40 mg | Capsule | 2x7 | 076848 | PKR 464.68 | PKR 33.19/capsule | Near median |
| Omelor | Omeprazole | 20 mg | Capsule | 2x7 | 076849 | PKR 297.39 | PKR 21.24/capsule | 8% above median |
| Omelor | Omeprazole | 40 mg | Powder for solution for infusion | 1's | 119262 | PKR 347.43 | PKR 347.43/vial/unit | No comparator |
| Omelor | Omeprazole | 40 mg | Solution for infusion | 1's | 119262 | PKR 347.43 | PKR 347.43/vial/unit | 41% below median |
| Paralord | Paracetamol | 500 mg | Tablet | 20x10 | 090132 | PKR 762.93 | PKR 3.81/tablet | 5% above median |
| Prenavo | Ondansetron | 8 mg | Tablet | 1x10 | 097384 | PKR 1,451.87 | PKR 145.19/tablet | 13% below median |
| Qlev | Levofloxacin | 250 mg | Tablet | 1x10 | 076833 | PKR 516.31 | PKR 51.63/tablet | 8% above median |
| Qlev Tabet | Levofloxacin | 500 mg | Tablet | 1x10 | 085213 | PKR 814.46 | PKR 81.45/tablet | Near median |
| Seftrix | Ceftriaxone | 500 mg | IM injection | 1's | 086387 | PKR 346.15 | PKR 346.15/vial/unit | Near median |
| Seftrix | Ceftriaxone | 500 mg | Injection | 1's | 086388 | PKR 346.15 | PKR 346.15/vial/unit | 6% above median |
| Seftrix | Ceftriaxone | 1 g | IV injection | 1's | 086389 | PKR 653.61 | PKR 653.61/vial/unit | 10% above median |
| Seftrix | Ceftriaxone | 250 mg | IM injection | 1's | 086390 | PKR 205.65 | PKR 205.65/vial/unit | Near median |
| Seftrix | Ceftriaxone | 250 mg | Injection | 1's | 086391 | PKR 205.65 | PKR 205.65/vial/unit | 7% above median |
| Woin | Clomifene citrate | 50 mg | Tablet | 1x10 | 099883 | PKR 346.83 | PKR 34.68/tablet | 17% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.